Topics

Erytech Pharma S.A.: ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019

17:05 EDT 17 Sep 2019 | FinanzNachrichten

Conference call and webcast on Wednesday, September 18at 2:30 pm CET/8:30 am EDT TRYbeCA1, Phase 3 trial for eryaspase in second line pancreatic cancer, progressing on planImmune modulation collabo...

Related Biotechnology, Pharmaceutical and Healthcare News

Original Article: Erytech Pharma S.A.: ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019

NEXT ARTICLE

More From BioPortfolio on "Erytech Pharma S.A.: ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored ND2A Group with offices at 677 Craig Rd, Suite 216, Creve Coeur, Missouri 63141 USA. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters here: Contact ND2A Group.

All rights reserved. All other trademarks recognized. Copyright © 2019 ND2A Group. Site developed by Alacrify Ltd

.